Todd Engel worked with heavy machinery in Maryland for decades. In early 2023, his doctor prescribed Ozempic, a GLP-1 drug, for diabetes. On New Year’s Eve, Engel experienced sudden vision loss in one eye. His doctor identified the problem as optic neuropathy, also known as NAION. This condition involves tiny strokes that cut off blood flow to the eye, and it cannot be treated with surgery.
When asked about Ozempic’s role, doctors said they were unaware of any connection. However, several months later, a study published in the journal JAMA Ophthalmology found higher rates of NAION among diabetic patients using Ozempic or its main ingredient, semaglutide. Unfortunately, Engel continued the medication until he lost vision in his other eye.
Growing Use of GLP-1 Drugs
More than 10% of Americans use GLP-1 drugs primarily for weight loss, according to a Gallup analysis. These drugs are prescribed for various issues, but they have a range of side effects. Engel filed a lawsuit against Novo Nordisk, the maker of Ozempic, claiming the company failed to warn about NAION risks. His lawsuit is among two main ongoing legal actions regarding GLP-1 drugs’ severe side effects.
In response, Novo Nordisk pointed to research challenging the connection between their product and NAION. They deem the lawsuits without essential grounds. Though a correlation between GLP-1 drugs and NAION exists, causation is not confirmed.
Understanding the Need for More Research
The JAMA Ophthalmology study linking NAION to GLP-1 drugs sparked debate. The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society noted their doubts about the study. They acknowledge a potential link but require further research. They do not advise stopping GLP-1 medications at present.
“This is not the type of study that can show the treatment caused NAION,”
says the statement by these medical groups.
The Role of Data and Reporting
The FDA has a database tracking adverse events related to drugs. While reporting is voluntary and unverified, it is essential for triggering deeper investigations. The database contains over 1,000 reports of optic neuropathy linked to GLP-1 drugs since 2024, out of almost 190,000 drug-related reports collected.
Novo Nordisk acknowledges that NAION and other severe conditions are rare in clinical trials. The company continues to share side effect data with the FDA, which has launched its own study on NAION risks. The FDA will decide on regulatory actions after completing its evaluation.
Legal Developments and Disputes
Attorney Jonathan Orent argues that current measures are inadequate for affected patients. He is involved in lawsuits alleging harm from GLP-1 drugs and states that drug makers should update warnings. This approach is necessary despite the rarity of conditions because trial sizes are limited.
Orent’s cases include 247 NAION claims and over 4,000 cases involving serious digestive issues. Lilly, maker of other GLP-1 drugs, plans to contest these claims robustly.
Data indicates 1,928 pancreatitis reports associated with GLP-1 drugs since 2024. Engel reflects on how prior warnings might have changed his decision to use Ozempic. He expresses sorrow over losing his vision and activities he can no longer enjoy.
Challenges in Reporting and Prescriptions
Complex metabolic diseases like diabetes complicate identifying drug-related problems. Dr. Mohammed Ali at Emory University notes the difficulty in reporting potentially preexisting conditions as drug-related incidents.
Robert Miller, a pharmacist at the West Texas Poison Control Center, highlights increased online GLP-1 drug sales with little supervision. This trend has led to more poison-control calls from patients experiencing side effects without medical oversight to report.
In courts, the issue of GLP-1 drug liability continues while patients and their families, like the Engels, seek resolution. Shelly Engel advocates for better warnings to prevent others from facing similar irreversible consequences.
NPR correspondent Sydney Lupkin contributed to this report.
